The QualityStocks Daily Friday, November 22nd, 2019

Today's Top 3 Investment Newsletters

StockMarketWatch (ASLN) +293.27%

QualityStocks (PHOT) +60.61%

Wolf of Penny Stocks (KAYS) +46.60%

The QualityStocks Daily Stock List

International Land Alliance, Inc. (ILAL)

TeleTrader, Stockopedia, Market Screener, OTC Markets, GlobeNewswire, StockNews, Stockwatch, Interactive Brokers, Simply Wall St, and Investors Hangout reported beforehand on International Land Alliance, Inc. (ILAL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

International Land Alliance, Inc. is a global land investment and development organization listed on the OTCQB. The Company’s emphasis is on acquiring attractive raw land chiefly in Northern Baja California, often within driving distance from Southern California. Its main goal is to sell desirable properties, at competitive prices, with favorable financing options for individual purchases and/or bulk purchases suitable for all kinds of investors and buyers. International Land Alliance has its corporate office in San Diego, California.

The Company offers the option of financing with a guaranteed acceptance on any purchase for every customer. Through removing the middleman, loans are approved directly by International Land Alliance. This provides easy and affordable financing terms. Additionally, there are no prepayment penalties, credit or background checks, and there are very competitively low interest rates.

International Land Alliance’s inventory includes properties that are residential, commercial, recreational, waterfront, ranch, hotel, and marina. The Company, by way of its wholly-owned subsidiary, International Land Alliance, S.A. de C.V, a Mexican corporation, is the owner of 123 residential lots and commercial lots consisting of 20-acres, known as Valle Divino, in Ensenada, Baja California. Furthermore, it is the owner of 1,344 residential lots and commercial lots consisting of 497-acres, known as Oasis Park Resort, in San Felipe, Baja California.

The Oasis Park Resort and Valle Divino Resort projects will undergo development as a second home resort or retirement destination in a planned community setting. The Villas Del Enologo at Rancho Tecate is a 2.6 Acre Parcel within the prestigious Rancho Tecate. It is a planned 24 -2B/2B Vineyard Villas with private wine cellar.

Overall, International Land Alliance owns four different real estate development properties consisting of almost 600 acres of land. These properties are all in southern California or Northern Baja California, Mexico. The Company has started final site preparation on its Valle Divino development. Valle Divino is part of a 1,250-acre master planned residential community overlooking the world-renowned Bajamar Ocean Front Hotel and Golf Course and the Pacific Ocean.

Yesterday, International Land Alliance announced it completed site preparation for Costa Bajamar Oasis, the Company’s new residential project at the Bajamar Ocean Front Golf Resort. This major development further allows International Land Alliance to start to leverage its recently announced agreement with CleanSpark, Inc. (CLSK) to deploy innovatively designed microgrid solutions. The Bajamar Ocean Front Golf Resort is a master planned golf community. It is 45 minutes south of the San Diego-Tijuana Border along the scenic toll road to Ensenada.

Mr. Zachary Bradford, CleanSpark’s Chief Executive Officer, said, “As we announced on November 5, 2019, we are excited to be working with ILAL as their exclusive partner in developing and designing energy solutions for all of their residential and commercial properties. Breaking ground at Costa Bajamar is the first step in what we believe will be a prosperous relationship. With construction beginning, CleanSpark will be providing a microgrid solution that will incorporate solar and energy storage assets into the existing power grid. ILAL expects to continue selling and developing additional properties which will provide both Companies increasing revenue opportunities.”

International Land Alliance, Inc. (ILAL), closed Friday's trading session at $0.60, off by 5.5118%, on 22,949 volume with 9 trades. The average volume for the last 3 months is 23,688 and the stock's 52-week low/high is $0.270099997/$5.00.

chart

Intrinsyc Technologies Corporation (ISYRF)

TeleTrader, PortfolioSharing, PR Newswire, Stockhouse, InvestorX, Ceo.ca, 4-Traders, Virtual-Strategy.com, Stockwatch, Wallet Investor, MarketBeat, and InvestorFile reported previously on Intrinsyc Technologies Corporation (ISYRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Intrinsyc Technologies Corporation is a leading provider of solutions for the development of embedded and Internet of Things (IoT) products. The Company provides comprehensive product development services, and also the industry’s highest-performance edge computing modules, to enable rapid commercialization of intelligent IoT products. OTCQX-listed, Intrinsyc Technologies is based Vancouver, British Columbia.

The Company partners with the world’s top OEMs (original equipment manufacturers) to create award-winning products. These include consumer mobile devices and embedded and IoT applications including robotics, wearables, automotive, medical, video conferencing, digital signage, industrial and consumer cameras, and many more.

Intrinsyc Technologies provides hardware, software, and services that enable next-generation intelligent connected products. Its solutions cover the entire development life cycle. These solutions help device makers and technology suppliers create differentiated products with faster time-to-market. Intrinsyc offers a portfolio of embedded computing modules based on Snapdragon™ technology from Qualcomm® Technologies, Inc., and i.MX processors from NXP Semiconductors N.V.

Intrinsyc Technologies announced in May of this year the Open-Q™ 212A SOM and Development Kit. The Open-Q™ 212A SOM is a compact (50mm x 46.5mm) pre-certified, production-ready embedded computing module. It is ideal for cost-sensitive home hub, home automation, and smart audio devices featuring voice control, AI, and wireless connectivity. It is powered by the Qualcomm® Home Hub 300 Platform based on the Qualcomm® APQ8009 System-on-Chip (SoC).

At the end of October, Lantronix, Inc.(LTRX) announced it entered into a definitive arrangement agreement to acquire all of the outstanding shares of Intrinsyc Technologies. The transaction, which is subject to approval by the shareholders of Intrinsyc along with other specified closing conditions, has been unanimously approved by the Board of Directors of both companies. The expectation is that it will be completed by the end of this calendar year or shortly thereafter. Lantronix is a worldwide provider of secure data access and management solutions for the industrial Internet of Things (IoT).

This transaction will bring immediate scale to Lantronix, adding complementary IoT computing and embedded product development capabilities and expanding its IoT market opportunity. Lantronix sees significant operating and product development synergies in the combined company. It expects the acquisition will be accretive in the first full quarter of operations.

Intrinsyc Technologies Corporation (ISYRF), closed Friday's trading session at $1.2299, up 2.9205%, on 2,342 volume with 6 trades. The average volume for the last 3 months is 27,515 and the stock's 52-week low/high is $0.80489999/$1.25997996.

chart

Jaguar Health, Inc. (JAGX)

Stock Twits, Market Screener, Stockwatch, Infront Analytics, Proactive Investors, Alpha Stock News, TradingView, Street Insider, Stockhouse, Investing.com, and Super Stock Screener reported previously on Jaguar Health, Inc. (JAGX), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Jaguar Health, Inc. is a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Its wholly-owned subsidiary is Napo Pharmaceuticals, Inc. Napo concentrates on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the worldwide marketplace from plants used traditionally in rainforest areas. Jaguar Health has its corporate office in San Francisco, California.

The Company’s mission is to identify human and animal health market opportunities where it can develop targeted products that leverage its extensive intellectual property (IP) portfolio, deep pipeline, and broad botanical library. Jaguar’s emphasis is naturally derived health solutions for humans and animals around the world.

Jaguar Health’s Mytesi® (crofelemer) product is approved by the U.S. FDA (Food and Drug Administration) for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. MYTESI® is not indicated for the treatment of infectious diarrhea.

Last week, Jaguar Health announced that Georgetown University's Data Safety Monitoring Committee (DSMC) reviewed the interim analysis for futility for the third-party, investigator-initiated Phase 2 HALT-D study evaluating the effectiveness of Mytesi® (crofelemer) for symptomatic relief in HER2 positive breast cancer patients receiving chemotherapy with trastuzumab, pertuzumab, and docetaxel or paclitaxel or trastuzumab, pertuzumab, carboplatin, and docetaxel. The DSMC has notified the Principal Investigator that the Study is allowed to enroll to completion. Enrollment in the Study now surpasses 85 percent. The treatment period for each patient is three months.

Total Mytesi prescription volume, which is the combination of new prescriptions and refills, grew 20 percent in Q3 of 2019 over Q3 of 2018.

Lisa Conte, Jaguar Health's President and Chief Executive Officer, said, "As we pursue development of pipeline indications for Mytesi, our goal is to optimize efficiency in the commercialization of Mytesi for the current HIV indication. We are pleased with the continued prescribing growth in Q3, in light of the recent approximately 50% decrease in the size of our Mytesi sales force and the recent realignment to focus on what we call ‘super targets' - family practitioners, general practitioners, internal medicine doctors, nurse practitioners, and physician assistants who were already prescribing anti-motility and anti-retroviral drugs and therefore were already engaging in conversations about diarrhea with their patients living with HIV/AIDS."

Jaguar Health, Inc. (JAGX), closed Friday's trading session at $0.5846, off by 1.7314%, on 477,136 volume with 1,303 trades. The average volume for the last 3 months is 996,324 and the stock's 52-week low/high is $0.563799977/$36.3860015.

chart

PASSUR Aerospace, Inc. (PSSR)

Zacks, Market Screener, Journal Transcript, Investors Hangout, OTC Markets, Stockwatch, MarketBeat, The Street, Stockhouse, Wallet Investor, Simply Wall St and Trading View reported beforehand on PASSUR Aerospace, Inc. (PSSR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

PASSUR Aerospace, Inc.’s mission is to improve global air traffic efficiencies through connecting the globe’s aviation professionals onto a single aviation intelligence platform. The Company is a worldwide leader in digital aviation operational excellence. PASSUR provides predictive analytics and decision support technology for the aviation industry, mainly to improve the operational performance and cash flow of airlines and the airports where they operate. Established in 1967, PASSUR Aerospace is headquartered in Stamford, Connecticut.

The Company maximizes airspace, runways, and gate usage, through using predictive analytics to determine how airports should be configured to get the most out of their capacity. PASSUR helps airlines, airports, and air traffic control prioritize departures to maximize capacity and minimize delays. PASSUR provides its proven, established capabilities to the international airline and airport industry, with solutions now implemented in Canada, Europe, and Latin America.

PASSUR’s information solutions are used at the five largest North American airlines, by greater than 60 airport customers, and used at the top 30 North American airports, by more than 100 business aviation customers, and by the U.S. government. PASSUR owns and operates the largest commercial passive radar network worldwide. The Company provides aircraft position updates every 1 to 4.6 seconds, powering a proprietary database that is accessible in real-time, and delivers timely and accurate information and solutions via PASSUR Aerospace’s industry leading algorithms and business logic included in its products.

Furthermore, 53 percent of all U.S. domestic commercial flights are managed with PASSUR predictive analytics for predicted arrival times, by using years of archived data, and real-time airspace analysis. This enables airlines and airports to always be ready for the aircraft.

In October, PASSUR Aerospace announced that it has contracted with Avianca Airlines to assist the airline with its "Avianca 2021 Transformation Strategy." PASSUR will first concentrate on enhancing efficient and optimal traffic flow management, both on the airport surface and in the airspace.

PASSUR's work supports one of the fundamental pillars of the transformation strategy – operational efficiency, including improving operational indicators like on-time performance, with a strong emphasis on the critically important El Dorado Airport operation.

The PASSUR services portfolio chosen by Avianca includes core competencies in airline operations performance analysis; air traffic management concepts of operation and best practices; and airport collaborative decision making (A-CDM). The services portfolio also includes airport and airspace simulation and modeling, and operational base-lining and outcomes measurement. All PASSUR Aerospace solutions are being consolidated onto the Company's Ariva platform. This platform will provide a single, common operating platform for customers to optimize their operations.

PASSUR Aerospace, Inc. (PSSR), closed Friday's trading session at $1.12, off by 9.6774%, on 800 volume with 1 trade. The average volume for the last 3 months is 633 and the stock's 52-week low/high is $1.04999995/$1.70000004.

chart

Sanara MedTech, Inc. (SMTI)

Zacks, Stock Chortle, Digital Journal, Stockwatch, Investors Hangout, InvestorsHub, TipRanks, Market Screener, StocksNewsFeed, Simply Wall St, TradingView, Investing.com, and Stockhouse reported previously on Sanara MedTech, Inc. (SMTI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Sanara MedTech, Inc. is a provider of surgical and chronic wound care products dedicated to improving patient outcomes. The Company develops, markets and distributes biotechnology products to physicians, hospitals, clinics, and all post-acute care settings. Sanara concentrates on developing and commercializing products in the areas of skin and wound care, including biofilm management. Biofilm management is an important step in the wound healing process. Sanara MedTech’s products sell in the North American advanced wound care and surgical tissue repair markets.

The Company previously went by the name WNDM Medical, Inc. It changed its corporate name to Sanara MedTech, Inc. in May of 2019. OTCQB-listed, Sanara MedTech is headquartered in Fort Worth, Texas.

Sanara MedTech sells and distributes CellerateRX® Surgical Activated Collagen® Adjuvant, HYCOL™ Hydrolyzed Collagen, BIAKŌS™ Antimicrobial Skin & Wound Cleanser, and PULSAR II™ Advanced Wound Irrigation System (AWI™). CellerateRX helps to provide a favorable environment for healing. The Activated Collagen® in CellerateRX® Surgical Powder is changing collagen’s role in the operating room.

CellerateRX’s® patented Activated Collagen fragments (CRXα®) are a fraction of the size of the native collagen molecules and particles found in other products. They provide the benefits of collagen to the body.

Sanara MedTech's Acute Care/Surgical Division continues to expand its Regional Sales Manager (RSM) and 1099 network. By January 2020, the division expects to grow to more than 20 RSM employees. The RSMs recruit, train, and support the 1099 independent sales team, which has tripled in size since the start of Q2 2019.

By the end of Q1 2020, Sanara MedTech's Wound Care Division plans to materially increase the number of RSM's covering the continental U.S. market. The RSMs work with skilled nursing facilities, home health care providers, wound centers, physician offices, and hospitals where Sanara’s products are used to treat patients.

Via a license agreement with its licensing and development partner, Rochal Industries LLC, Sanara plans to launch its BIAKŌS™ Antimicrobial Barrier Film and CuraShield™ No Sting Skin Protectant products in Q2 of 2020. Sanara continues to work with Rochal on several impactful new medical device designs with plans to bring them to market in the coming years.

Furthermore, Sanara MedTech is working with Rochal to develop a debrider, a flowable scaffold that can be used to fill tunneling or undermining wounds, an oxygen transport device for use in hypoxic wounds, and a liquid bandage to treat skin tears and other similar wounds and skin conditions.

Sanara MedTech, Inc. (SMTI), closed Friday's trading session at $10.50, even for the day, on 50 volume with 1 trade. The average volume for the last 3 months is 3,127 and the stock's 52-week low/high is $2.00/$14.00.

chart

GrowLife, Inc. (PHOT)

Zacks, CannabisMarketCap, Green Rush Review, Stockopedia, Best Medical Marijuana Stocks, Stockwatch, Wall Street Alerts, Simply Wall St, Market Screener, Energy and Capital, InvestorsHub, TradingView, TMXmoney, Investing.com, Stockhouse and GlobeNewswire reported earlier on GrowLife, Inc. (PHOT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

GrowLife, Inc. is one of the nation’s most recognized indoor cultivation product and service providers. The Company provides farming soil, hydroponics equipment, organic plant nutrients, and other products to specialty grow operations in the U.S. Its goal is to become the nation’s largest cultivation service provider for cultivating organics, herbs and greens and plant-based medicines. GrowLife is headquartered in Kirkland, Washington.

GrowLife has a complete selection of cultivation products combined with logistics and distribution services. The Company’s focus is on helping responsible cultivation operations efficiently control supply costs, manage build-out investments, track supply usage, and streamline workflows. GrowLife provides essential goods and services via a network of local representatives covering the U.S. and Canada, regional centers, as well as its e-Commerce team.

GrowLife’s retail locations are in Encino, California; Portland, Maine; and Calgary, Alberta. The Company also has its GrowLife Commercial operations.

In July, GrowLife announced that it launched a new platform for its recently majority acquired EZ-CLONE Enterprises, Inc. (EZ-CLONE) cloning and propagation company to serve as the commercial hemp cloning industry’s resource for innovation. The new platform, ezclonehemp.com, is now set to be a trusted resource for cultivators to look for products and education on plant cloning and propagation, purposely designed for hemp growers. The Company received the patent for the design of its EZ-CLONE Pro Commercial Cloning System, “Aeroponics System with Rack and Tray”.

GrowLife Chief Executive Officer, Marco Hegyi, said, “As experts in plant cultivation, we understand that hemp growers are seeking additional information and products that enable them to grow consistent, high-volume hemp plants, and cloning is one of the best ways to achieve this. Through this new platform we clearly define the benefits of cloning, visitors can learn more about our products, make purchases and learn how to grow hemp from clones.”

Recently, GrowLife reported more than $4.4m in Revenue in the first six months of 2019 versus $4.6m in Revenue for all of 2018. The Company reported Gross Profit for the six-month period ending on June 30, 2019 of $1.4 million, versus $187,900 in the same period last year. This represents a 669 percent increase.

GrowLife, Inc. (PHOT), closed Friday's trading session at $0.0053, up 60.6061%, on 66,443,460 volume with 1,030 trades. The average volume for the last 3 months is 8,021,195 and the stock's 52-week low/high is $0.002099999/$0.0114.

chart

Tapinator, Inc. (TAPM)

NetworkNewsWire, Zacks, TipRanks, Market Screener, Simply Wall Street, 4-Traders, Stockopedia, TradingView, Stockhouse, InvestorsHub, Wallet Investor, and TMX Money reported beforehand on Tapinator, Inc. (TAPM), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Tapinator, Inc. is a developer and publisher of category leading applications (apps) for mobile platforms. The Company develops and publishes mobile games and apps on the iOS, Google Play, and Amazon platforms in North America, Europe, and Asia. Its library includes more than 300 titles that, collectively, have realized greater than 450 million mobile downloads. This includes noteworthy properties such as Video Poker Classic, Solitaire Dash, as well as Crypto Trillionaire. Established in 2013, Tapinator is based in New York, New York. The Company has product development and marketing teams located in North America, Europe, and Asia.

Tapinator generates revenues via the sale of branded advertising and through consumer transactions. This includes in-app purchases and subscriptions.

Tapinator previously announced the January 31, 2019 worldwide release of Crypto Trillionaire exclusively on Apple's iOS platform. The Company joined forces with the game's developer, Robot Cake Games of Hannover, Germany, to bring the innovative, best-in-class idle tapper game to mobile players around the world. Subsequent to its initial international launch on iOS, Crypto Trillionaire was featured by Apple as a "New Game We Love," in 152 countries, including the United States. Crypto Trillionaire is the first of a number of planned major releases for Tapinator's category-leading Games & Apps business for this year.

Tapinator announced this past April that it launched a major update to Video Poker Classic, the leading video poker game on mobile. The Company’s new 2.0 version brings multi-hand capability, a popular casino feature, to the game's core single-hand gameplay. Tapinator introduced Triple Play, Five Play, and Ten Play for all of its 39 game types. With the new version, Video Poker Classic has the richest offering of any video poker title on mobile devices, in terms of game types, gameplay formats (Single Hand, Triple Play, Five play, Ten play) and overall functionality.

Moreover, Tapinator is developing a new social casino game. The unique mobile title is scheduled for launch in Q4 of this year. The upcoming game features a slot mechanic, with inventive metagame systems, which have proven their success in the world of real money gaming. The title is made possible via the Company's recent licensing deal with a major European real-money slots developer.

The real-money version of the product is now a top performing slot game across more than 200 online casinos in several European nations. Tapinator will be announcing the details of the partnership closer to the game's launch.

Tapinator, Inc. (TAPM), closed Friday's trading session at $0.055, up 37.50%, on 682,898 volume with 36 trades. The average volume for the last 3 months is 96,825 and the stock's 52-week low/high is $0.015499999/$0.069899998.

chart

BioCorRx, Inc. (BICX)

NetworkNewsWire, Barchart, Zacks, Stockwatch, Proactive Investors, Wallet Investor, The Street, InvestorsHub, Stockhouse, Marketbeat, Stockopedia, Equity Clock, YCharts, and Uptick Newswire reported on BioCorRx, Inc. (BICX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, BioCorRx, Inc. is a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders. The Company offers an inventive approach to the treatment of substance abuse addiction and related disorders. The BioCorRx® Recovery Program is its non-addictive, medication-assisted treatment (MAT) program. BioCorRx is headquartered in Anaheim, California. The Company’s shares trade on the OTC Markets Group’s OTCQB. The Company additionally conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals.

A healthcare solutions enterprise, BioCorRx is at the vanguard of alcohol and opioid addiction treatment. Its dedication is on improving the quality of life for recovering addicts. Its recovery program is an outpatient medication-assisted treatment (MAT) program for alcohol and opioid drug addiction.

The BioCorRx® Recovery Program comprises two primary components. The first component consists of an outpatient implant procedure performed by a licensed physician. This implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can considerably lessen physical cravings for alcohol and opioids. Naltrexone can also prevent opioid overdose following relapse.

The second component of the program is a Cognitive Behavioral Therapy (CBT) program. It is tailored purposely for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The BioCorRx® Recovery Program is used by a network of independently owned and operated treatment centers situated across the U.S.

Recently, BioCorRx announced it completed a private placement. The Company issued 400,000 common stock shares at a price of $15.00 per share, for total proceeds of $6 million. The $15.00 price paid by two investors, one of whom is Louis Lucido, a Director, represents a 282 percent premium to the market price of $3.93 per share, as of the market close on April 1, 2019.

A part of the capital will be used to fund the launch and expansion of BioCorRx’s weight loss program in the coming months. In addition, funds will be used to further the Company’s product development pipeline in the addiction treatment field. Also, this month, BioCorRx announced that Mr. Joseph J. Galligan was appointed as Senior Advisor to the Company. Mr. Galligan, CFA, was formally an Executive Vice President and Portfolio Manager at DoubleLine Capital LP. Previously, he served as Senior Vice President of Apex Mortgage Capital, Inc. In addition, he was a Managing Director and Portfolio Manager at The TCW Group, Inc.

Brady Granier, Chief Executive Officer, President and Director of BioCorRx, stated, “Over the years, Joe has been a major supporter of the Company and we are delighted to have him join the team as a senior advisor. His broad capital markets experience and proven leadership will be invaluable as we prepare to list on NASDAQ and further execute on our growth strategy.”

BioCorRx, Inc. (BICX), closed Friday's trading session at $3.80, up 32.4042%, on 467 volume with 7 trades. The average volume for the last 3 months is 1,900 and the stock's 52-week low/high is $2.46000003/$10.00.

chart

Kaya Holdings, Inc. (KAYS)

Stockflare, Tip Ranks, InvestorsHub, MarketWatch, Daily Marijuana Observer, Zacks, OTC Markets, Equity Clock, Stockhouse, The Street, Microcap Daily, Wallet Investor and Barchart reported previously on Kaya Holdings, Inc. (KAYS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Kaya Holdings, Inc., via its subsidiaries, produces, distributes and sells legal premium medical and recreational cannabis products. These include flower, concentrates and oils, and cannabis-infused foods. Kaya Holdings incorporated a subsidiary, Marijuana Holdings Americas, Inc., a Florida corporation (MJAI) in January of 2014. Through entities controlled by MJAI, Kaya centers on opportunities in the legal recreational and medical marijuana sectors in the United States. OTCQB-listed, Kaya Holdings is headquartered in Fort Lauderdale, Florida.

The Company operates four Kaya Shack™ OLCC (Oregon Liquor Control Commission) licensed marijuana retail stores to serve the legal medical and recreational marijuana market in Oregon. It developed the Kaya Shack™ brand for its retail operations. Kaya Holdings began its own medical marijuana grow operations for the cultivation and harvesting of legal marijuana in April 2015.

Kaya has completed the processes necessary to launch its own home delivery service in Portland and Salem, Oregon. It expects to operate four cars at first, with more cars to be added as demand requires and as Kaya expands into other cities in Oregon.

Kaya operates a 12,000 square foot warehouse facility licensed for growing and processing that it is operating pursuant to a management agreement while it await license transfer review. The Company’s 26 acre farm just obtained zoning approval to construct the 80,000+ square feet of indoor/outdoor growing facilities and is presently undergoing OLCC Licensing review.

Kaya Holdings has launched a subsidiary named Kaya Worldwide to explore several global opportunities for the expansion of Kaya Medical and Recreational Cannabis Operations. In addition, Kaya issued an update on its U.S. operations and the scheduling of the Company’s Annual Shareholder Video and Conference call.

Furthermore, Mr. Craig Frank, Kaya Holdings’ Chief Executive Officer, said, “To date we have engaged foreign counsel and allocated manpower and resources to potentially secure participation in large-scale, cultivation-for-export opportunities in 2 separate countries.”

In December 2018, Kaya Holdings announced that it had to postpone the Annual Shareholder and Webinar Conference Call until after the New Year. The Company will hold the event to coincide with the Annual Report, which is currently in the process of completion.

Kaya Holdings, Inc. (KAYS), closed Friday's trading session at $0.0755, up 46.6019%, on 10,512,658 volume with 1,664 trades. The average volume for the last 3 months is 146,673 and the stock's 52-week low/high is $0.05/$0.128999993.

chart

The Bon-Ton Stores, Inc. (BONTQ)

Penny Stock Hub, Zacks, Stockopedia, Investor Place, Investing.com, Stockflare, 4-Traders, InvestorsHub, StreetInsider, YCharts, Barchart, Stockhouse, and TradingView reported on The Bon-Ton Stores, Inc. (BONTQ), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets Group’s OTCQB and established in 1898, The Bon-Ton Stores, Inc. operates 250 stores. These include nine furniture galleries, in 23 states in the Northeast, Midwest and upper Great Plains under the Bon-Ton, Bergner's, Boston Store, Carson's, Elder-Beerman, Herberger's and Younkers nameplates. The Bon-Ton Stores has corporate headquarters in York, Pennsylvania and Milwaukee, Wisconsin.

The Company’s stores offer a wide variety of national and private brand fashion apparel and accessories for women, men and children. The stores also offer cosmetics and home furnishings.

The Bon-Ton Stores has been taking action over the past number of months to boost improved performance and strengthen its financial position. The Company has taken another step forward in its efforts through filing voluntary petitions for a court-supervised restructuring under Chapter 11.

On February 4, 2018, The Bon-Ton Stores, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Its varied stores throughout the U.S. are open. In addition, its e-commerce and mobile platforms are operating normally.

Recently, The Bon-Ton Stores announced that it received a signed letter of intent (LOI) from an investor group consisting of DW Partners, Namdar Realty Group (including its partner Mason Asset Management) and Washington Prime Group. This investor group proposes to acquire The Bon-Ton Stores as a going concern in a Bankruptcy Court-supervised sale process.

The Bon-Ton Stores and this investor group are in the process of finalizing an asset purchase agreement in advance of an auction. The auction is now scheduled to be held on Monday, April 16, 2018.

Mr. Bill Tracy, The Bon-Ton Stores’ President and Chief Executive Officer, said, "We are pleased to have received this signed letter of intent and are advancing our discussions with the investor group to complete an asset purchase agreement as we proceed toward the court-supervised auction. With the help of our advisors, we will evaluate all qualified bids and are committed to maximizing value and pursuing the best path forward for the Company and our stakeholders.”

The Bon-Ton Stores, Inc. (BONTQ), closed Friday's trading session at $0.0348, up 93.3333%, on 138,252 volume with 17 trades. The average volume for the last 3 months is 9,071 and the stock's 52-week low/high is $0.0026/$0.059999998.

chart

Protalex,  Inc. (PRTX)

StreetInsider, Zacks, TopStockAnalysts, and OTCPicks reported on Protalex,  Inc. (PRTX), and we highlight the Company as well, here at the QualityStocks Daily Newsletter. 

Protalex,  Inc.  is a clinical-stage Biopharmaceutical Company based in Florham Park, New Jersey. Its emphasis is on the development of a class of drugs for treating autoimmune and inflammatory diseases. These include RA  (Rheumatoid Arthritis) and ITP  (Immune Thrombocytopenia). The Company’s lead product is PRTX-100. This is a formulation of a proprietary, highly purified form of Staphylococcal Protein A, which is an immunomodulatory protein produced by bacteria.  Protalex’s shares trade on the OTC Markets Group’s OTCQB.

  Rheumatoid arthritis (RA) is an autoimmune disease. RA is a disorder in which the body’s immune system mistakenly attacks the joints. Immune Thrombocytopenia (ITP) is a blood disorder. ITP can result in easy or excessive bleeding and bruising because of the body’s inability to form blood clots.

Pre-clinical data indicate that PRTX-100 may have the potential to treat ITP through reducing the immune-mediated destruction of the platelets. Protalex has open IND’s for the treatment of RA and ITP in the United States, and in Europe, an open IMPD for ITP.

Protalex’s PRTX-100 can  (at very low concentrations) bind to human B-lymphocytes and macrophages and to modulate immune processes. PRTX-100 has been granted Orphan Drug Designation in the United States and in Europe for the treatment of ITP. This status provides commercial exclusivity benefits, tax credits for certain research, potential research grants and a waiver of the New Drug Application user fee in the United States. Currently, it is the subject of clinical studies in the U.S. and Europe.  

PRTX-100 is administered as a short intravenous infusion.  The following patents have been granted for PRTX-100:  U.S. Patent No. 9,370,552 (‘552 patent) is a continuation patent to initial U.S. patent No. 7,211,258 (Protein A compositions and methods of use) filed in 2002 and issued with method of treatment claims for RA, juvenile RA, and systemic lupus erythematosus (SLE). The ‘552 patent expands the method of treatment of PRTX-100 to include type 1 diabetes.  

European Patents No. 2,570,136 and 2,206,511 (national patents in place in France, Germany, Italy, Spain, Switzerland, and the UK) includes composition claims relating to numerous autoimmune diseases (RA, ITP, juvenile RA, psoriasis, myasthenia gravis) and dosage expansion. 

Canadian patents No. 2,894,098 and No. 2,481,282 comprise method of treatment claims relating to RA and SLE.   Japanese patent No. 5,523,796 claims compositions for treating psoriasis, scleroderma, Crohn’s Disease, myasthenia gravis, ulcerative colitis, psoriatic arthritis, as well as pemphigus vulgaris.

Recently, Protalex announced that following a planned interim analysis of data from the fourth dose cohort of its European Phase 1b study of PRTX-100 (PRTX-100-203 Study) in adults with persistent/chronic Immune Thrombocytopenia (ITP), it initiated enrollment in the fifth and highest dose cohort of this dose-escalating study.

The first patient in the final cohort was recently dosed in the United Kingdom at 24 micrograms/kg. This the highest dose of PRTX-100 used in any clinical trial to date. One of the three patients treated in the fourth dose cohort (18 micrograms/kg) attained a protocol defined platelet response.

Protalex,  Inc. (PRTX), closed Friday's trading session at $0.02, up 33.3333%, on 1,600 volume with 2 trades. The average volume for the last 3 months is 3,513 and the stock's 52-week low/high is $0.000199999/$0.219999998.

chart

Boston Therapeutics, Inc. (BTHE)

MissionIR,  Tiny Gems, SmallCapVoice, PennyStocks24,   FeedBlitz, Wall Street Mover,  RedChip, TaglichBrothers,  Stock News Now, TopPennyStockMovers, and Information Solutions Group  reported  earlier  on Boston Therapeutics, Inc. (BTHE), and  today we are reporting on  the Company, here at the QualityStocks Daily Newsletter.

Boston Therapeutics, Inc. is a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases. The Company’s product pipeline  centers  on developing and commercializing therapeutic molecules  that  address diabetes and inflammatory diseases. OTCQB-listed,  Boston Therapeutics is based in Lawrence, Massachusetts.

The Company’s  product pipeline includes BTI-320. This is a  non-systemic, non-toxic,  chewable complex carbohydrate-based compound. The design of it is to lessen post-meal glucose elevation. BTI-320 is a proprietary polysaccharide. 

BTI-320 works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes, which break down complex carbohydrates into simple sugars, reducing  the availability of glucose for absorption into the bloodstream. 

Boston Therapeutics  entered a  clinical trial agreement with Joslin Diabetes Center to be the lead clinic  in a Phase II study of BTI-320. In addition,  the Company’s  product pipeline  includes IPOXYN™. This is an injectable anti-necrosis drug. The design of it at first is to treat lower limb ischemia associated with diabetes.  

Boston Therapeutics’  product pipeline also  includes OXYFEX™. This product can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events. OXYFEX™ is  the Company’s  veterinary facsimile to IPOXYN™.

Furthermore, Boston Therapeutics  developed and markets SUGARDOWN®. This is a non-systemic,  complex carbohydrate-based dietary food supplement. The design of SUGARDOWN® is to support healthy blood glucose.

SUGARDOWN®, in its present formulation, is a natural sugar blocker dietary supplement product made completely from a non-digestible sugar molecule, which can help people maintain healthier weight levels. It is the first chewable tablet of its kind. 

In 2015, Boston Therapeutics announced that its affiliate, Advance Pharmaceutical Company Limited (APC), began the  SUGARDOWN®  clinical trial in Hong Kong. Advance is evaluating the effect of  SUGARDOWN®  on Post-Prandial Hyperglycemia in Chinese subjects with Pre-Diabetes.  The lead clinical site is the Department of Medicine, The Chinese University of Hong Kong  (CUHK), Prince of Wales Hospital. 

In April 2017, Boston Therapeutics and  Advance Pharmaceutical announced the fully funded new trial plans to support the safety and efficacy of BTI-320, starting with a randomized, placebo-controlled, double-blinded, multi-center, global study on type 2 diabetic (T2D) patients.

More recently, Boston Therapeutics announced that effective sugar reduction with the investigative BTI-320 formulation necessitates only one tablet. Findings were confirmed by the most recent proof-of-concept study conducted in high-risk Chinese subjects with pre-diabetes. A formulation, in the form of a dietary supplement, is currently available as SUGARDOWN®, SUGARBLOCK and SUGARBALANCE in the Unites States and Asia.

Moreover, in December, Boston Therapeutics announced that it expanded its partnership with Advance Pharmaceutical Company Limited (APC) to distribute in Korea. Following the extension of the licensing and distribution agreement with APC, a registered formulation, marketed as a food supplement under the name SUGARBALANCE is now available in Korea. This significant shipment marks a start to the sales of SUGARBALANCE in the territory. 

Boston Therapeutics, Inc. (BTHE), closed Friday's trading session at $0.012, up 71.4286%, on 37,200 volume with 7 trades. The average volume for the last 3 months is 43,453 and the stock's 52-week low/high is $0.007/$0.05.

chart

WRIT Media Group, Inc. (WRIT)

SeriousTraders, Tip.us, Real Pennies, StocksToBuyNow, Pennystockmania, Great Penny Picks, and SmallCapVoice reported earlier on WRIT Media Group, Inc. (WRIT), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

WRIT Media Group, Inc. is a diversified media and software business whose shares trade on the OTC Markets. The Company’s portfolio of wholly-owned businesses includes Front Row Networks; Amiga Games; Retro Infinity, Inc.; and Pandora Venture Capital. WRIT Media Group is headquartered in Los Angeles, California.

WRIT Media’s operations include digital currency software development, including trading platforms and Blockchain solutions, content production and distribution; and video game distribution by way of mobile platforms. Its Front Row Networks produces and distributes live event programming for international digital broadcast to movie theaters and online streaming.

WRIT’s Amiga Games is a software company. Amiga is restarting the Amiga brand through publishing retro video games on smartphones and tablets. WRIT’s Retro Infinity is a video game distribution site. It publishes video games from Amiga, Atari and other "retro" brands on contemporary smartphones, tablets and consoles.

Additionally, WRIT’s Pandora Venture Capital is a financial technology company. Pandora has an emphasis on its digital currency, Pelecoin, a new generation of digital currency, Blockchain technology solutions, and also the CrypFXPro trading platform. WRIT Media's proprietary CrypStock digital trading platform will provide the technology that will support the creation and trading platform for Pelecoin and other digital currencies.

WRIT Media Group plans to integrate its Pelecoin Blockchain technology into products and applications that can be used to make it as easy to spend digital currencies, cryptocurrencies, and Pelecoin, as it is to spend US Dollars. Through the Company’s acquisition of Pandora Venture Capital, WRIT assumed a skilled management team with backgrounds in payments, telecom, and digital currency.

Recently, WRIT Media Group announced a number of technology innovations within its Pelecoin cryptocurrency system. The Company plans over the next year to enhance its software platform through adding more features and by expanding its ecosystem through new products.

During the past several months, WRIT Media's development team has built the core functionality of its digital currency system. The Company now offers a new feature that enables users to mine four cryptocurrencies at the same time by employing Pelecoin's proprietary mining algorithm software. The core system is complete. The foundation is ready for Pelecoin to expand and become a strong platform suitable for broader adoption, with updated core features and extensive new ones for its ecosystem.

WRIT Media Group, Inc. (WRIT), closed Friday's trading session at $0.018, up 40.625%, on 15,004 volume with 5 trades. The average volume for the last 3 months is 6,326 and the stock's 52-week low/high is $0.009999999/$0.042139999.

chart

eWellness Healthcare Corp. (EWLL)

Penny Stock Prodigy and StockHideout reported earlier on eWellness Healthcare Corp. (EWLL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Culver City, California-based eWellness Healthcare Corp. develops a telemedicine platform. This platform is for providing Distance Monitored Physical Therapy programs. These programs are for pre-diabetic, cardiac, and health challenged patients via contracted physician practices and healthcare systems. The Company has launched PHZIO. The design of this telemedicine platform is to extend and scale a physician’s practice. eWellness Healthcare is the first physical therapy telemedicine enterprise to provide insurance reimbursable real-time distance monitored treatments. eWellness Healthcare lists on the OTC Markets Group’s OTCQB.

The Company’s business model is to license its PHZIO platform to any physical therapy (PT) clinic in the United States and/or have large-scale employers use its PHZIO platform as a completely PT monitored corporate wellness program. eWellness Healthcare’s PHZIO is a Physical Therapy Telemedicine platform. It extends a traditional practice online.

The chief features of the PHZIO platform include video treatment protocols, real-time patient monitoring, patient induction forms, a patient video journal, and post treatment evaluations. In addition, main features include integrated billing, patient metrics, and user administration & customization.

Moreover, PHZIO scales a practice’s billable rates. It also provides tools to make growing a business easier. Pertaining to the Patient Dashboard, the PHZIO Dashboard enables clients to login securely to access prescribed treatment protocols. PHZIO is user-friendly and highly reliable to operate for PT and Patient. Furthermore, it’s a total on-line PT telemedicine intervention system.

eWellness Healthcare has launched a PHZIO PT clinic on-boarding website. The site includes a telehealth profitability calculator to illustrate to prospective PT clinics the additional profits they can make through using the PHZIO platform.

eWellness Healthcare anticipates adding Artificial Intelligence (AI) tools and predictive analytics into its PHZIO platform by the end of this year. The anticipation is that the new AI and predictive analytics will combine the Company’s existing remote monitoring capabilities with machine learning and intelligent analytics, which take advantage of patient health data to improve healthcare outcomes.

Evolution Physical Therapy has added eWellness Healthcare's Telehealth PT Services at its four clinical locations in Los Angeles, California. This includes Culver City, Playa Vista, Beverly Hills, and Brentwood. Mr. Darwin Fogt, Chief Executive Officer of eWellness Healthcare, owns Evolution Physical Therapy.

Recently, eWellness Healthcare and Total Release Physical Therapy announced an Integration & Marketing Agreement. Total Motion Release Seminars (TMR) is a proprietary physical therapy methodology developed by Mr. Tom Dalonzo-Baker, MPT. TMR is a full-body oriented assessment and treatment approach. TMR helps patients lessen their pain and impairments which limit their function. The treatment approach is created to allow physical therapists to interact and treat their patients remotely. The expectation is that integration with PHZIO will be extensively adopted within the TMR community.

eWellness Healthcare Corp. (EWLL), closed Friday's trading session at $0.00846, up 32.1875%, on 5,041,000 volume with 72 trades. The average volume for the last 3 months is 2,687,481 and the stock's 52-week low/high is $0.006099999/$0.338999986.

chart

The QualityStocks Company Corner

Willow Biosciences Inc. (CSE: WLLW)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW).

Willow Biosciences (CSE: WLLW) (OTCQB: CANSF) on Thursday announced its financial and operating results for the three and nine months ended September 30, 2019. Among other highlights, the company reported that it ended the quarter with around $23.2 million of working capital and $24 million of cash on hand. To view the full press release, visit http://cnw.fm/2PpHt.

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (CSE: WLLW), closed Friday's trading session at $0.65, up 3.17%, on 3,000 volume with 2 trades. The average volume for the last 3 months is 84,987 and the stock's 52-week low/high is $0.529999971/$5.25.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) was featured today in a publication from CBDWire, examining how the 2018 Hemp Farming Act was a godsend for the hemp industry. The legislation classified cannabis with less than 0.3 percent THC as hemp and removed it from its list of controlled substances. Dubbed by some as a catalyst for explosive growth, the bill gave farmers in all 50 states leeway to grow the versatile cash crop under regulation.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hemp-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Friday's trading session at $0.4538, up 0.844444%, on 198,126 volume with 79 trades. The average volume for the last 3 months is 93,206 and the stock's 52-week low/high is $0.399800002/$1.6875.

Recent News

chart

HTC Extraction Systems (TSX.V: HTC)

The QualityStocks Daily Newsletter would like to spotlight HTC Extraction Systems (TSX.V: HTC).

HTC Extraction Systems (TSX.V: HTC) today announced its entry into a November 21, 2019 share and purchase agreement (“SPA”) with Starling Brands Inc., a party at arm's length to HTC. Under the SPA, HTC will acquire all issued and outstanding shares of Kase Farma Inc., a subsidiary of Starling, and upon completion of the acquisition, Kase Farma will be a wholly owned subsidiary of HTC. To view the full press release, visit http://cnw.fm/O4Enq.

HTC Extraction Systems (TSX.V: HTC) has developed and optimized proprietary technologies designed for biomass extraction, distillation and purification of ethanol and ethanol-based solvents used for the hemp biomass and cannabidiol (“CBD”) industry, as well as gas and liquid extraction. HTC’s extraction & purification systems are engineered to large-scale to reduce capital and operating costs while delivering superior performance measured by reduced energy usage, lowered emissions and improved quality of the product produced.

Advanced Extraction Technologies

For more than 14 years, HTC has developed and optimized proprietary technology and purification systems used for biomass, gas and liquid extraction. These technologies include:

  • LCDesign® – Low-cost design for modular gas, liquid and biomass extraction systems optimizes plant design, thus reducing capital and operating costs.
  • PDOEngine™ – Software-based design algorithms accurately model and simulate gas, liquid and biomass extraction processing.
  • Delta Solvents™ – Custom-designed, ethanol-based solvent mixtures and additives that optimize production and reduce costs. Technology development is being conducted at HTC’s sponsored research facilities at the University of Calgary.

Delta Purification® Technology

HTC’s patented Delta Purification® technology will purify, recycle and reuse the extraction ethanol used in the CBD extraction process while managing and reducing any CBD waste losses through the re-extraction of all wastes collected from the purified ethanol. Current and new technologies include:

  • Delta CBD Reclaiming System: Reclaiming and purifying ethanol for use in CBD extraction from biomass. Reduces required heat to prevent damage of the chemical attributes of the CBD molecule, allowing extracted CBD to meet food-grade targets for human consumption.
  • Delta Solvent Reclaiming System: Reclaiming and purifying ethanol-based solvents, such as single, mixed and formulated amines, for use in natural gas processing and post-combustion CO2 capturing processes.
  • Delta Glycol Reclaiming System: Reclaiming and purifying glycols, such as mono-ethylene glycol and tri-ethylene glycol for use in natural gas dehydration processes.

Hemp Biomass and Tolling Contracts

HTC has entered into a hemp biomass tolling agreement for the 2019 crop year involving a supply of hemp biomass from a hemp grower in Saskatchewan, Canada. The hemp grower utilizes five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process and extract CBD FSO distillate from the hemp biomass. As a tolling fee payment, HTC will receive a percentage of the extracted CBD FSO distillate for its processing, extraction, purification and distillation services.

Additional hemp biomass tolling contracts with producers and hemp biomass providers are being negotiated in the U.S. for the 2020 hemp crop growing year. HTC will provide “local-to-grower” drying-to-biomass storage capability and transportation of dried biomass to an HTC, location to be determined, future US based, extraction facility. HTC is also in negotiation with a 60,000-acre, recognized Canadian farm leader, who is a significant hemp biomass producer, for a similar hemp biomass tolling contract.

re3™ Technology

Large users of ethanol and solvents for plant oil extraction demand reduced capital and operating costs. HTC’s re3™ (reclaim, recycle, reuse) technology can save up to 30% of the required fluid costs. The increasing cost of new extraction ethanol, combined with the cost of used ethanol disposal, creates a unique opportunity whereby the re3™ technology will create cost savings, while meeting environmental responsibilities.

The growth of ethanol and CO2 used in CBD production has created a new demand for reliable commercial scale ethanol reclaimer systems. The Delta Purification® ethanol system meets this new demand.

Sales and Offtake Agreements

HTC intends to leverage its relationship with its related entity, Purely Canada Foods™, to provide sales and distribution for its Ingredient CBD market under the brand of Purely Canada Hemp™, Purely Canada CBD™, Purely Canada Cannabinoids™. Purely Canada Hemp™ will develop risk managed multi-year ingredient supply contracts with its existing and new Global Food, Beverage and Animal Food Industry Customers.

Project Construction

HTC has focused the Canadian implementation of its BOOM (build, own, operate and maintain) extraction tolling strategy on a location near Regina, Saskatchewan. HTC is currently constructing a 19,000-square-foot GMP Euro compliant extraction tolling facility on six acres of land that will include biomass processing, extraction, implementation of DeltaSolv™ technologies and Delta Purification® systems, distillate and refining equipment, laboratory quality control and testing operations, and on-site office and admin facilities.

Leadership

Chairman, CEO and Director Lionel Kambeitz is a recognized professional in business development and international business relations. He has played a founding role in many other Canadian and U.S.-based companies. Kambeitz has executive experience in a variety of industries including energy, agriculture, food production engineering, and manufacturing.

Jeff Allison, Senior Vice President, Chief Financial Officer and Director, has over 20 years of experience in corporate finance and business development. Prior to joining HTC in 2005, Allison as Vice President assisted with the founding and setup of CUCORP Financial Services in Saskatchewan.

HTC Extraction Systems (TSX.V: HTC), closed Friday's trading session at $0.30, up 27.6596%, on 195,800 volume with 32 trades. The average volume for the last 3 months is 124,671 and the stock's 52-week low/high is $0.079999998/$1.24.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Commercial-stage developer of innovative medical devices Endonovo Therapeutics Inc. (OTCQB: ENDV) reported its financial results for the third quarter of 2019 via a press release issued on November 19, 2019 (http://nnw.fm/x0ATU). According to the announcement, Endonovo’s revenues increased by 153% to $54,039 in the third quarter of 2019, compared to $21,306 in the third quarter of 2018. Revenues for the nine months that ended on September 30, 2019 increased 293% to $161,720, as compared to $41,132 for the same period last year.

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s targeted pulsed electromagnetic field (tPEMF) transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone. 

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy. 

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Steven C. Levin, M.D., Scientific Advisory Board Member
Dr. Steven C. Levin is the regional medical director at Johns Hopkins School of Medicine and medical director at Howard County General Hospital in Columbia, Maryland. Additionally, he is an assistant professor at Johns Hopkins School of Medicine, Department of Anesthesiology. Dr. Levin is currently the co-chair of the Opioid Stewardship Clinical Community as well as a clinical design team leader of the Musculoskeletal Center in the Johns Hopkins Health System. Additionally, Dr. Levin has previously served on the medical school facility at Yale University and at University of Pittsburgh Medical Center. Dr. Levin received his undergraduate degree from University of Pennsylvania and medical degree at the University of Pittsburgh. He completed his residency and fellowship at the University of Pittsburgh Medical Center. His membership in professional and scientific societies has included the American Society of Anesthesiology, American Pain Society, American Society of Regional Anesthesia, Society in Anesthesia and International Association for the Study of Pain.

Peter Novak, M.D., Ph.D., Scientific Advisory Board Member
Dr. Peter Novak is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a board-certified neurologist and a board-certified autonomic specialist. He is a member of the American Academy of Neurology, American Autonomic Society and the Autonomic Board of United Council for Neurologic Subspecialties. Dr. Novak graduated from medical school in Bratislava, Slovakia, and completed his neurology residency at Ohio State University. He also completed postdoctoral studies focusing on cardiovascular and autonomic research at Charles University (Prague) the University of Montreal, McGill University (Montreal) and the Mayo Clinic. He has special interests in autoimmune, small fiber and autonomic neuropathies, autoimmune, postural orthostatic tachycardia syndrome and multiple system atrophy. He has written over 70 papers and presented at numerous conferences.

Geoffrey Abrams, M.D., Scientific Advisory Board Member
Dr. Geoffrey Abrams is an assistant professor of orthopedic surgery at the Stanford University School of Medicine and the director of sports medicine for Stanford’s varsity athletes. He specializes in orthopedic sports medicine and arthroscopy of the shoulder, knee and elbow as well as upper extremity joint replacement surgery. Dr. Abrams is a member of the American Academy of Orthopedic Surgeons (AAOS) and the American Orthopedic Society for Sports Medicine (AOSSM), among others, and currently serves as assistant team physician for the NFL’s San Francisco 49ers as well as head team physician for a number of Stanford University varsity athletic teams. He is actively involved in research focusing on the role of inflammatory mediators, and microRNA in particular, on cartilage and tendon damage. Dr. Abrams received his undergraduate degree from Stanford University and his doctorate of medicine from the University of California – San Diego. He completed his residency in orthopedic surgery at Stanford University and went on to receive additional training in Orthopedic Sports Medicine and Shoulder Surgery at Rush University Medical Center in Chicago, Illinois. Dr. Abrams has authored or co-authored over 60 peer-reviewed scientific articles, over 20 book chapters, has presented original research at numerous national and international scientific meetings, and serves as a reviewer for numerous sports medicine scientific journals.

Dr. William Li, Scientific Advisory Board Member
Dr. William Li is CEO and co-founder of the Angiogenesis Foundation. He trained in the lab of Dr. Judah Folkman, pioneer of the angiogenesis field, and has been actively engaged in angiogenesis research and clinical development for 30 years. Under Dr. Li’s leadership, the foundation has developed a unique social enterprise model based on value-creating collaborations with leading biopharmaceutical and medical device companies. Dr. Li is actively engaged in identifying unmet needs in the healthcare space for which clinical and cost-effective technology can offer beneficial solutions. He is a graduate of Harvard, and completed his medical residency training at Massachusetts General Hospital in Boston. He serves as advisor and consultant to leading global public and private companies.

Mykol Larvie, Scientific Advisory Board Member
Recipient of three Harvard Medical Student Teaching awards in Principal Clinic Experience, Mykol Larvie is currently a radiologist in the Cleveland Clinic’s Divisions of Nuclear Medicine and Neuroradiology as well as the director of Functional and Molecular Neuroimaging. With a completed internship in the Department of Medicine as well residency in the Department of Radiology and fellowship in the Division of Neuroradiology at the Massachusetts General Hospital, Dr. Larvie specializes in PET examinations of the brain performed typically for the evaluation of neurodegenerative disease, seizure and tumor. He delivers didactic lectures and case conferences to residents and fellows six times per year and serves as a mentor and advisor to medical students, residents and fellows.

Nathan L. Guerette, Scientific Advisory Board Member
Nathan L. Guerette is the director and president of the Female Pelvic Medicine Institute of Virginia; an associate clinical professor in the division of Urogynecology and Pelvic Reconstructive Surgery at the Medical College of Virginia; a full clinical professor in Urogynecology and Pelvic Reconstructive Surgery at the Riverside Regional Medical Center; and the Robotic Surgery director at the Chippenham and Johnston Willis Medical Center. With a completed fellowship in urogynecology and pelvic reconstructive surgery at the Cleveland Clinic Foundation, Dr. Guerette has won seven awards in the medical and humanitarian departments. He has made nine media appearances, some of which were on PBS and NBC News. He has three board certifications and has ran a surgical mission trip to Trujillo, Peru, through Bon Secours.

Dr. Ashling O’Connor, Scientific Advisory Board Member
Currently a surgeon at the Comprehensive Breast Health Center of the Lahey Medical Center, Dr. O’Connor has won seven awards in the surgical department. She has completed a surgical internship at the Mater Misericordiae Hospital in Dublin as well as a breast surgery fellowship at the University of Massachusetts Interdisciplinary Breast Fellowship. She mentors medical students and surgical residents both in the operating room and in a clinical setting and enjoys biking and triathlons as well as trail and marathon running. She is certified in the Hidden Scar technique in breast surgery as well as in the advanced cardiac life support and is a member of the Protocol Review Committee Umass Memorial Medical Center, the New England Surgical Society and the American College of Surgeons.

Samir Awad, Scientific Advisory Board Member
Samir Awad has worked for the Department of Veterans Affairs since 2000. He has served as the operative care line associate executive, chief of general surgery, and medical director of the Surgical Intensive Care Unit at the MEDVAMC. Dr. Awad’s areas of specialty include liver, pancreas, and acute care surgery, as well as minimally invasive surgical procedures. He is a member of the Association for Academic Surgeons, the Society of University Surgeons, the American College of Surgeons, the Surgical Infection Society, and the Society for Critical Care Medicine. Dr. Awad has authored more than 100 peer-reviewed and invited publications and is the recipient of numerous awards for surgical and research achievements. Dr. Awad is certified by the American Board of Surgery and Surgical Critical Care.

Endonovo Therapeutics Inc. (ENDV), closed Friday's trading session at $0.0035, up 2.9412%, on 2,820,504 volume with 45 trades. The average volume for the last 3 months is 5,235,160 and the stock's 52-week low/high is $0.0031/$0.040899999.

Recent News

chart

Quest Patent Research Corp. (OTCQB: QPRC)

The QualityStocks Daily Newsletter would like to spotlight Quest Patent Research Corp. (OTCQB: QPRC).

New York City-based Quest Patent Research (OTCQB: QPRC) is offering investors a unique opportunity to play a part in the intellectual property (“IP”) monetization space. A recent article discussing the company reads, “‘IP monetization poses significant risks. To view the full article, visit http://nnw.fm/l8iDs.

Quest Patent Research Corp. (OTCQB: QPRC) is a New York City-based intellectual property (IP) asset management firm operating through majority-owned and controlled operating subsidiaries to deliver financial, strategic and legal resources for IP monetization. Quest currently owns, controls or manages over 115 patents across 11 intellectual property portfolios (https://www.qprc.com/portfolio). The company generates revenues from patent licensing fees of its IP property portfolios and from licensed packaging sales.

Quest creates shareholder value through investment and management interests in intellectual property assets, such as patents, trademarks, copyrights, novel inventions and trade secrets. Through its business, shareholders have the opportunity to participate across a broad portfolio of dynamic assets in the burgeoning intellectual property space.

Objectives

Invention, protection and commercialization of IP require a deep understanding of dynamic technologies, market fundamentals, competitive landscapes and engagement strategies. Often, IP asset owners/stakeholders lack the requisite resources, experience and/or capacity to access the latent value of their IP assets and opportunities. Quest seeks to bridge this gap, partnering with asset owners – such as inventors, businesses, corporations and law firms – to help them fully realize the value of IP assets through:

  • IP Valuation
  • Structured Licensing Programs
  • Patent Prosecution
  • Partial or Full Liquidity
  • Portfolio Evaluation
  • Portfolio Maintenance
  • Legal Advisory
  • Attorney/Investor Referral
  • Patent Acquisition/Liquidation

At Quest, each partnership is treated as its own entity, with its own focused management comprised of Quest employees and seasoned industry associates. Many of technologies are placed in a wholly owned subsidiary of Quest, benefitting from the broader expertise of the company’s leadership.

Management

Quest’s management team delivers a wealth of experience in strategic business management, intellectual property, finance and marketing. The company’s internal resources, in tandem with its external network of financial, legal and managerial professionals, can develop creative solutions to the myriad of challenges involved in monetizing IP. Quest’s structured diligence and deployment procedures mitigate risks, maximize returns and deliver value to IP owners and shareholders alike.

Quest CEO and President Jon Scahill was the founder and managing director of the Urban-Rigney Group, LLC, a private consultancy specializing in new business/new venture development, operations optimization, and strategic analysis. Prior to launching his consultancy business, Mr. Scahill held numerous positions in sales and marketing, technical management, and product development in the consumer products/flexible packaging arena. Mr. Scahill holds a B.S. in chemical engineering from the University of Rochester, an MBA from Rochester’s Simon Graduate School of Business, and a JD from Pace University Law School. He is a registered patent attorney admitted to practice in New York, Florida, the District of Columbia and before the United States Patent and Trademark Office.

Quest Chief Technology Officer Timothy Scahill recently completed a merger and buyout of Managed Services Team LLC, an IT Managed Services provider. Prior to Managed Services Team, he was president of Layer 8 Group Inc., which merged with Structured Technologies Inc. to form Managed Services Team LLC. In his roles he was responsible for business strategy, acquisition, execution, as well as financial management. Mr. Scahill’s entrepreneurial acumen and proven record of successful management with sole discretionary responsibility, demonstrate the scope of his capability and his value to delivering results. He successfully completed his term on the boards of the Upstate New York Technology Council and Pariemus Rochester. Mr. Scahill completed a six-year term as secretary, executive council and a seat on the board of directors for Habitat for Humanity. He has served as president of the Western New York chapter of The Entrepreneurs Organization and continues to serve on the board as accelerator chair. Mr. Scahill is currently performing Cyber Intelligence, Security and Information Assurance work for an undisclosed organization.

Peter LaFauci is president of CFO Solutions, a Rochester, NY-based consulting firm offering knowledge-based financial and accounting solutions for emerging to medium-size companies. Mr. LaFauci is a seasoned executive with over 25 years of proven success in developing, leading and executing strategy in both publicly and privately held companies within the advertising, software development, internet, manufacturing and emerging technologies sectors. Peter possesses strong research and analytical skills as well as interpreting, summarizing and communicating financial and business information to others. Mr. LaFauci is a graduate of Saint Bonaventure University.

Quest Patent Research Corp. (OTCQB: QPRC), closed Friday's trading session at $0.0125, up 13.6364%, on 146,246 volume with 9 trades. The average volume for the last 3 months is 269,727 and the stock's 52-week low/high is $0.004499999/$0.039999999.

Recent News

chart

InsuraGuest Inc.

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Inc..

InsuraGuest Inc. recently signed a contract with Cal-Vegas Ltd.(R) to provide its Red Lion Inn & Suites(R) property in South Carolina with specialized insurance coverage for guests utilizing InsuraGuest’s proprietary InsurTech software (http://nnw.fm/c2WKx). To view the full article, visit http://nnw.fm/g7E26.

InsuraGuest Inc. is a SaaS (Software-as-a-Service) company utilizing its proprietary flagship InsurTech software platform to provide specialized insurance products to end users in the business-to-business (B2B) and business-to-consumer (B2C) markets. The company’s first focus is on the B2B hotels and vacation rentals sectors, where its API integrates with the clients’ property management systems to offer guests a specialized guest protection policy. The platform and policy combination “InsurTech” product helps transfer the exposure to liability away from the client/property while guests benefit from potential accident and loss coverage during their stay.

InsuraGuest’s platform is currently capable of integrating with approximately 70 different hotel and vacation rental property management systems, giving it access to roughly 40,000 properties worldwide.

The company continues to pursue expansion opportunities and recently signed a Letter of Intent with a master general agent in the United Kingdom and Europe to distribute its platform and products to hotel and vacation rental markets in those regions, as well as plans to expand to Asia in 2020.

Protecting Guests, Enhancing Customer Experience

InsuraGuest is the first line of defense for both the property and the guest.

InsuraGuest is purchased by the hotel or vacation rental “property,” which offers the policy to each registered guest and its occupants for an additional fee. The specialized policy affords coverage for theft of personal property while in the hotel, as well as accidental medical expense and accidental death and dismemberment, up to the policy limits of $2,500 to $50,000.

Market Opportunity

The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United State alone, where there are approximately 4.5 million second homes are being managed by a third-party rental company.

With distribution in Europe and the United States, InsuraGuest’s demographics combined will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit.

Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Specialized Guest Protection Policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.

Business Highlights

  • Targeting hotels and vacation rentals, a multi-billion-dollar industry
  • Providing the first line of defense in case of accident, loss or death
  • Expanding distribution reach with footing in European hotel and vacation rental markets
  • Expansion into Asia by 2020

Executive Team

Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.

Anderson earned a BS undergraduate degree in Consumer Studies with an emphasis in Architecture as an undergraduate at the University of Utah. He subsequently earned his Master’s in Business Administration. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.

Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends.

Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.

Christopher J. Panos Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.

Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018. He also has served as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.

Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.


Recent News

chart

Hemptown USA

The QualityStocks Daily Newsletter would like to spotlight Hemptown USA.

Hemptown USA, a privately owned grower of full-spectrum, feminized hemp using premium-seed genetics, operates a farm operation with more than 500 acres dedicated to the cultivation of nonpsychoactive cannabigerol (“CBG”). The company’s recent harvest positioned it to be the largest producer of CBG in North America.

Hemptown USA, headquartered in Central Point, Oregon, is a proven grower of full-spectrum hemp biomass grown using premium seed genetics that contain less than 0.3% THC and exceptionally high cannabinoid (CBD) content of up to 20%. The company's "soil to oil" methodology combines seasoned professionals working in hand-picked agricultural microclimates located in Oregon's famed Emerald Triangle, Kentucky and Colorado.

Hemptown has exclusive rights to 1 million rare CBG (cannabigerol) seeds genetically programmed to yield from 15% to 20% full-spectrum non-intoxicating cannabinoids. As a result of a long-standing relationship with the one of the world's most respected cannabis breeding companies – Oregon CBD Seeds – Hemptown is positioned to be a leading CBG producer in the U.S. in 2019 and beyond.

In 2018 Hemptown's harvest from its Oregon hemp farm was 150,000 pounds of full-spectrum biomass with CBD content hovering around 17%. 2018 harvest revenue expected to range from $8.1 million to $12.6 million. The company is scaling up operations in 2019 to meet market demands and projects it will reap over 1,000,000 pounds. By 2020, Hemptown projects potential revenues in the $100 million to $200 million range are possible once additional farming operations are at full strength.

Growth Strategy

By 2020, Hemptown anticipates it will have more than 3,000 acres in several states dedicated to hemp farming. Expansion plans include increasing in-house extraction capabilities to boost profit margins by providing additional CBD and CBG isolates and distillation services. Development of business-to-business channels as well as new products and formulations for the direct-to-consumer market, along with several strategic acquisitions, are also key to Hemptown's growth strategy.

Hemptown plans to expand distribution and growing operations globally through strategic partnerships and development of contracts with leading Fortune 500 brands in European markets. The company intends to grow its IP portfolio by developing a proprietary water-soluble cannabinoid delivery system. Not to be confused with water-compatibility, water-soluble cannabinoids combine seamlessly with other liquids, have a superior shelf life, and deliver dramatically increased efficacy to the consumer.

Branded Products

Hemptown's first in-house branded product line combines the inspiring strength found in the unbridled nature that surrounds the company's original hemp farm in the Siskiyou Klamath region of Oregon. Sisku is set to redefine the cannabinoid packaged goods space with an elegant look, clean feel and potent, reliable efficacy.

Custom product lines can also be created for any product manufacturer as Hemptown brings GMP and ISO accredited processing facilities online in 2019. Together with Oregon CBD Seeds and Hemptown's product sciences team, Hemptown will be able to create custom, proprietary full-spectrum CBD and CBG oils and pure isolates.

Management Team

Company Chairman Rod Wolterman founded Hemptown's Oregon operations in 2016. He has extensive experience in the cannabis sector having been active within the space since 1998. Wolterman has also acted as a private equity investor in numerous medical marijuana dispensaries and cultivation operations in southern California.

CEO John Cummings has over 20 years of experience in finance, marketing, sales and project management. He led the compliance and special projects efforts for Kings Garden, one of the largest vertically integrated operators in California. Cummings also spent a year in Europe launching the continent's first GMP and ISO-accredited cultivation and manufacturing facility.

Dr. Gordon Chiu is chief science officer for Hemptown USA. He has more than 15 years of combined domestic and international experience in biomedical, chemical, cosmetic, medical and technology industries. A graduate of Rensselaer Polytechnic Institute with a master's degree from Seton Hall University, Chiu is leading Hemptown's cannabinoid research team and is responsible for filing IP patents, specifically in the areas of water-solubility, bioavailability and peptide sequencing.


Recent News

chart

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) was featured today in a publication from HempWireNews, examining how the hemp industry, it seems, is on a wild roller coaster that won’t seem to stop. For starters, the crop has for decades had a taboo aspect to it because of its relation to the infamous marijuana. Still, it has numerous other non-intoxicating uses, and in 2018, Congress passed the Farm Bill, effectively legalizing the cultivation of industrial hemp. The sector quickly grew carried by demand for the increasingly popular hemp extract cannabidiol (CBD), and in just one short year, the industry was flooded with thousands of unregulated CBD products.

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed Friday's trading session at $2.64, off by 7.6923%, on 4,677,370 volume with 14,960 trades. The average volume for the last 3 months is 2,030,201 and the stock's 52-week low/high is $2.00/$8.43999958.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products (CSE: PLUS) (OTCQB: PLPRF), a leading cannabis-branded products company in the United States, recently kicked off a multichannel campaign strategy to raise national awareness. An article discussing the company reads, “The campaign features new PLUS hemp-CBD products, which consumers can purchase online and have shipped to them in 43 states (http://cnw.fm/49Z0r). To view the full article, visit http://cnw.fm/9TpOe.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Friday's trading session at $1.8388, off by 0.605405%, on 67,334 volume with 135 trades. The average volume for the last 3 months is 42,882 and the stock's 52-week low/high is $1.08749997/$6.00810003.

Recent News

chart

Trxade Group Inc. (TRXD)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (TRXD).

Third quarter financial results reported recently show Trxade Group Inc. (OTCQB: TRXD) is continuing to maintain a profitable integrated pharmacy services operation while working to redefine the health care industry for the betterment of small independent pharmacists nationwide. Trxade Group’s acquisition of Community Specialty Pharmacy, LLC last year continues to drive the company’s revenue benchmarks, delivering sales that lifted the company to record revenues of $2.3 million for the quarter and nine-month year-to-date revenues of $5.7 million, which amount to increases of 173 percent and 126 percent over previous year figures, respectively, according to the company’s news release (http://nnw.fm/eDu17).

Trxade Group Inc. (TRXD) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade's overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company's pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, "E-Bay/Kayak-like" technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the "consumer side" of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called "Delivmeds" (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade's Managed Services Organization ("TrxadeMSO") enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient's information, thereby ensuring appropriate medication coverage based on the patient's location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade's fair online market platform targets the nation's retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE's programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks ("PAC") to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry.
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE's advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process.

Management Team

Trxade's management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary

Suren Ajjarapu has served as Trxade's chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer

Prashant Patel has served as Trxade's full-time president and COO, and as a director since the company's acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (TRXD), closed Friday's trading session at $1.25, off by 0.398406%, on 1,100 volume with 2 trades. The average volume for the last 3 months is 3,176 and the stock's 52-week low/high is $0.230000004/$1.60000002.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF) was featured today in a publication from CBDWire, examining how cannabidiol is without a doubt the breakout star among medicines this decade, if not the century. The cannabis extract is a darling of the medicine, sports, and the health and wellness communities, with potent and versatile medicinal properties that make it effective against a wide range of diseases.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Friday's trading session at $0.72, off by 18.6441%, on 2,948,648 volume with 1,688 trades. The average volume for the last 3 months is 1,232,336 and the stock's 52-week low/high is $0.469300001/$4.38000011.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) today announced that John Griese has joined the company as its chief operating officer ("COO"). Griese brings over 30 years of executive consumer packaged goods ("CPG") and global cannabis operations experience and, in his role as COO, will be responsible for driving continuous improvements across all operating assets and leading supply chain management for Supreme Cannabis' diverse portfolio of products. To view the full press release, visit http://cnw.fm/R2Jl0.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Friday's trading session at $0.5521, off by 6.4237%, on 679,989 volume with 402 trades. The average volume for the last 3 months is 550,093 and the stock's 52-week low/high is $0.432000011/$1.7888.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America (OTCQB: MCOA) was featured today in the 420 with CNW by CannabisNewsWire. In New Jersey, lawmakers are abandoning plans of legalizing marijuana through the legislature and are now looking to enter the proposal on the 2020 ballot for the voters to decide.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed Friday's trading session at $0.1715, off by 12.0513%, on 422,094 volume with 170 trades. The average volume for the last 3 months is 322,012 and the stock's 52-week low/high is $0.023/$2.10599994.

Recent News

chart

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (OTCQB: SHRG), a diversified holdings company, has found success by employing its unique Blue Ocean Strategy, a method of selling its proprietary product line through its Elepreneur independent distributors. To view the full article, visit http://nnw.fm/zIH8d.

Sharing Services Global Corporation (SHRG), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRG has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services Global Corporation ’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders – Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services Global Corporation , and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services Global Corporation , at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services Global Corporation (SHRG), closed Friday's trading session at $0.10, off by 10.8734%, on 77,500 volume with 13 trades. The average volume for the last 3 months is 34,823 and the stock's 52-week low/high is $0.065800003/$0.3944.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.